請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26605完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳漢忠(Han-Chung Wu),林欽塘(Chin-Tarng Lin) | |
| dc.contributor.author | Tzu-Wen Tai | en |
| dc.contributor.author | 戴慈文 | zh_TW |
| dc.date.accessioned | 2021-06-08T07:17:11Z | - |
| dc.date.copyright | 2008-08-14 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-26 | |
| dc.identifier.citation | (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350, 1047-1059.
(2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717. Adams, G.P., and Weiner, L.M. (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23, 1147-1157. Allred, D.C., Mohsin, S.K., and Fuqua, S.A. (2001). Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8, 47-61. Arpino, G., Bardou, V.J., Clark, G.M., and Elledge, R.M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6, R149-156. Baloglu, E., Miller, M.L., Roller, E.E., Cavanagh, E.E., Leece, B.A., Goldmacher, V.S., and Chari, R.V. (2004). Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorg Med Chem Lett 14, 5885-5888. Baselga, J. (2001). The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 37 Suppl 4, S16-22. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14, 737-744. Beral, V., Banks, E., and Reeves, G. (2002). Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360, 942-944. Borst, M.J., and Ingold, J.A. (1993). Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114, 637-641; discussion 641-632. Breedveld, F.C. (2000). Therapeutic monoclonal antibodies. Lancet 355, 735-740. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., et al. (2001). Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7, 1490-1496. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat Med 9, 653-660. Carter, P. (2001). Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1, 118-129. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754-758. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Godwin, J., Gray, R., Hicks, C., James, S., et al. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087-2106. Claus, E.B., Risch, N., and Thompson, W.D. (1991). Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48, 232-242. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17, 2639-2648. Cohen, S.M., and Ellwein, L.B. (1990). Cell proliferation in carcinogenesis. Science 249, 1007-1011. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., and Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300. Dillman, R.O., Johnson, D.E., Shawler, D.L., and Koziol, J.A. (1988). Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48, 6097-6102. Easton, D.F., Ford, D., and Bishop, D.T. (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56, 265-271. Eerola, H., Aittomaki, K., Asko-Seljavaara, S., Nevanlinna, H., and von Smitten, K. (2002). Hereditary breast cancer and handling of patients at risk. Scand J Surg 91, 280-287. Esteva, F.J., Valero, V., Booser, D., Guerra, L.T., Murray, J.L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H.A., et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20, 1800-1808. Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., and Boyle, P. (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592. Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3, 391-400. Fisher, E.R., Gregorio, R.M., Fisher, B., Redmond, C., Vellios, F., and Sommers, S.C. (1975). The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36, 1-85. Garnett, M.C. (2001). Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 53, 171-216. Grillo-Lopez, A.J., Hedrick, E., Rashford, M., and Benyunes, M. (2002). Rituximab: ongoing and future clinical development. Semin Oncol 29, 105-112. Guillemard, V., and Uri Saragovi, H. (2004). Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23, 3613-3621. Haffty, B.G., Yang, Q., Reiss, M., Kearney, T., Higgins, S.A., Weidhaas, J., Harris, L., Hait, W., and Toppmeyer, D. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24, 5652-5657. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. Harari, P.M. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11, 689-708. Harding, J., and Burtness, B. (2005). Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41, 107-127. Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96. Huang, S.M., Bock, J.M., and Harari, P.M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59, 1935-1940. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007). Cancer statistics, 2007. CA Cancer J Clin 57, 43-66. Johnson, D.A., and Laguzza, B.C. (1987). Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res 47, 3118-3122. Johnson, J.R., Ford, C.H., Newman, C.E., Woodhouse, C.S., Rowland, G.F., and Simmonds, R.G. (1981). A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro. Br J Cancer 44, 472-475. Karashima, T., Sweeney, P., Slaton, J.W., Kim, S.J., Kedar, D., Izawa, J.I., Fan, Z., Pettaway, C., Hicklin, D.J., Shuin, T., et al. (2002). Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8, 1253-1264. Key, T., Appleby, P., Barnes, I., and Reeves, G. (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94, 606-616. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844. Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497. Kohler, G., and Milstein, C. (1992). Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 24, 524-526. Liu, A.Y., Robinson, R.R., Hellstrom, K.E., Murray, E.D., Jr., Chang, C.P., and Hellstrom, I. (1987). Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 84, 3439-3443. Mandler, R., Kobayashi, H., Hinson, E.R., Brechbiel, M.W., and Waldmann, T.A. (2004). Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64, 1460-1467. Mann, G.J., Thorne, H., Balleine, R.L., Butow, P.N., Clarke, C.L., Edkins, E., Evans, G.M., Fereday, S., Haan, E., Gattas, M., et al. (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8, R12. Martinez, V., and Azzopardi, J.G. (1979). Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3, 467-488. Maxfield, F.R., and McGraw, T.E. (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5, 121-132. McKeage, K., and Perry, C.M. (2002). Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243. McKean-Cowdin, R., Spencer Feigelson, H., Xia, L.Y., Pearce, C.L., Thomas, D.C., Stram, D.O., and Henderson, B.E. (2005). BRCA1 variants in a family study of African-American and Latina women. Hum Genet 116, 497-506. McManus, M.J., and Welsch, C.W. (1984). The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 54, 1920-1927. Milenic, D.E., Brady, E.D., and Brechbiel, M.W. (2004). Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3, 488-499. Moulder, S., and Hortobagyi, G.N. (2008). Advances in the treatment of breast cancer. Clin Pharmacol Ther 83, 26-36. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752. Petersen, B.H., DeHerdt, S.V., Schneck, D.W., and Bumol, T.F. (1991). The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res 51, 2286-2290. Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D.F., Evans, C., Deacon, J., and Stratton, M.R. (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91, 943-949. Pike, M.C., Spicer, D.V., Dahmoush, L., and Press, M.F. (1993). Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15, 17-35. Ravdin, P.M., Cronin, K.A., Howlader, N., Berg, C.D., Chlebowski, R.T., Feuer, E.J., Edwards, B.K., and Berry, D.A. (2007). The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356, 1670-1674. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988). Reshaping human antibodies for therapy. Nature 332, 323-327. Sanderson, R.J., Hering, M.A., James, S.F., Sun, M.M., Doronina, S.O., Siadak, A.W., Senter, P.D., and Wahl, A.F. (2005). In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11, 843-852. Saxena, S., Chakraborty, A., Kaushal, M., Kotwal, S., Bhatanager, D., Mohil, R.S., Chintamani, C., Aggarwal, A.K., Sharma, V.K., Sharma, P.C., et al. (2006). Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 7, 75. Schrama, D., Reisfeld, R.A., and Becker, J.C. (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5, 147-159. Schubert, E.L., Lee, M.K., Mefford, H.C., Argonza, R.H., Morrow, J.E., Hull, J., Dann, J.L., and King, M.C. (1997). BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60, 1031-1040. Schwartz, R.S. (2004). Paul Ehrlich's magic bullets. N Engl J Med 350, 1079-1080. Seidman, A.D., Fornier, M.N., Esteva, F.J., Tan, L., Kaptain, S., Bach, A., Panageas, K.S., Arroyo, C., Valero, V., Currie, V., et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19, 2587-2595. Shen, W.C., Ballou, B., Ryser, H.J., and Hakala, T.R. (1986). Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. Cancer Res 46, 3912-3916. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712. Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-10874. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100, 8418-8423. Travis, R.C., and Key, T.J. (2003). Oestrogen exposure and breast cancer risk. Breast Cancer Res 5, 239-247. van 't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536. Verheul, H.M., Voest, E.E., and Schlingemann, R.O. (2004). Are tumours angiogenesis-dependent? J Pathol 202, 5-13. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20, 719-726. Weigelt, B., Peterse, J.L., and van 't Veer, L.J. (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591-602. Weng, W.K., and Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940-3947. Yarden, Y. (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4, S3-8. Yelton, D.E., and Scharff, M.D. (1981). Monoclonal antibodies: a powerful new tool in biology and medicine. Annu Rev Biochem 50, 657-680. Zafir-Lavie, I., Michaeli, Y., and Reiter, Y. (2007). Novel antibodies as anticancer agents. Oncogene 26, 3714-3733. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26605 | - |
| dc.description.abstract | 乳癌為先進國家中女性常見的癌症。在美國，乳癌排名女性癌症罹患率的第一位，同時也是女性癌症死亡率第二位。而在台灣，乳癌為女性癌症死因之第四名。乳癌同時也是造成女性死亡年齡提早的主要癌症死因之一。目前乳癌在早期治療後，五年存活率可高達90%以上，然而發生轉移後的五年存活率則降至50%以下。乳癌常見的治療方式有外科手術切除、放射線治療以及化學治療。手術切除與放射線治療較適用於早期治療，待腫瘤發生轉移或再度復發後，化學治療為較常見的治療方式。然而化學治療常使病人產生較大的副作用，因此療效有限。近年來，由於治療性抗體相關的研究與發展，發現治療性抗體能更專一性地針對腫瘤細胞並使癌症治療能更有效進行。目前美國食品藥物管理局已認可多種治療性抗體，並使之得以使用於臨床上治療癌症。在本篇研究中，我們建立 11種單株抗體可專一性辨認乳癌細胞 MDA-MB-231，並對正常細胞具極低的親和性。我們也經由不同的方法分析並探討這些單株抗體之特性。在對11種不同癌細胞株的酵素免疫分析法 (ELISA)實驗中，測得單株抗體 MDA-Ab 1-1, MDA-Ab 2-6, MDA-Ab 3-1, MDA-Ab 5-9, MDA-Ab 6-9, MDA-Ab 7-2, MDA-Ab 8-1,MDA-Ab 9-2, MDA-Ab 10-3 及 MDA-Ab 11-1 表現出不同目標蛋白質結合反應。我們再藉由 ELISA、西方墨漬法、免疫染色及流式細胞測定，得知這些單株抗體之特性。經由西方墨漬法的實驗結果，這些單株抗體辨認出不同分子量的標的蛋白。而根據細胞與組織切片染色，我們清楚確認有些單株抗體的標的蛋白表現在腫瘤細胞的細胞膜上。這些單株抗體對腫瘤具有高度的專一性，因此有潛力在未來應用於診斷乳癌病人及發展標靶治療。 | zh_TW |
| dc.description.abstract | Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer deaths in American women. In Taiwan, breast cancer is higher than those of other cancers in women aged 40 to 60 years and is the fourth leading cause of cancer deaths. The five-year survival rate of localized breast cancer cases is higher than 90% while that of the metastatic status will be below 50%. The breast carcinoma in situ is usually treated by surgical mastectomy and lumpectomy combined with radiotherapy. The major treatment for metastatic breast cancer is chemotherapy nowadays. However, the traditional chemotherapy may be accompanied with several side effects, including nausea, vomiting, diarrhea, hair loss, weight loss, fatigue, anemia, edema, heart failure and liver and kidney damage. Furthermore, chemotherapy can easily induce chemoresistent outcomes in cancer cells. Based on the disadvantages of chemotherapy, it is necessary to develop new modalities of therapy such as targeted therapies.
During the past decades, therapeutic antibodies have been applied extensively in clinical treatment of cancers due to the well-developed technology of generating monoclonal antibodies (mAbs). Up to now, several mAbs have been approved by the US Food and Drug Administration (FDA) for used in various clinical settings, including cancer therapy. In this study, we have generated 11 mAbs (MDA-Ab 1-1, MDA-Ab 2-6, MDA-Ab 3-1, MDA-Ab 5-9, MDA-Ab 6-9, MDA-Ab 7-2, MDA-Ab 8-1,MDA-Ab 9-2, MDA-Ab 10-3 and MDA-Ab 11-1) which exhibited higher binding affinities for cancer cells than those for normal cells. The specificity of these mAbs was subsequently confirmed by the ELISA, Western blotting, immunostaining and flow cytometric assays. The results from Western blot analysis revealed that these mAbs recognized different target proteins. The localization of these target proteins on the plasma membrane of cancer cells were further confirmed using cancer cell lines and human surgical specimens of breast cancer. In conclusion, we have generated several mAbs against breast cancer cells. These specific mAbs are useful to identify the tumor antigens or develop ligand-targeted therapeutics for breast cancer. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T07:17:11Z (GMT). No. of bitstreams: 1 ntu-97-R95444001-1.pdf: 3254820 bytes, checksum: 7e372a6b225961a93cd851659a36a995 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 中文摘要…………………………………………………………………………1
Abstract…………………………………………………………………………...2 Introduction……………………………………………………………………….4 Materials and methods……………………………………………………………20 Results…………………………………………………………………………….30 Discussion…………………………………………………………………………36 Figures and figure legends………………………………………………………...42 Reference………………………………………………………………………….57 | |
| dc.language.iso | en | |
| dc.subject | 標靶治療 | zh_TW |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | 單株抗體 | zh_TW |
| dc.subject | 治療性抗體 | zh_TW |
| dc.subject | ligand-targeted therapy | en |
| dc.subject | breast cancer | en |
| dc.subject | monoclonal antibody | en |
| dc.subject | therapeutic antibody | en |
| dc.title | 乳癌專一性單株抗體的製備與功能之探討 | zh_TW |
| dc.title | Generation and Characterization of Monoclonal Antibodies against Breast Cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林中梧(Chung-Wu Lin) | |
| dc.subject.keyword | 乳癌,單株抗體,治療性抗體,標靶治療, | zh_TW |
| dc.subject.keyword | breast cancer,monoclonal antibody,therapeutic antibody,ligand-targeted therapy, | en |
| dc.relation.page | 65 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2008-07-29 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 3.18 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。